Illumina Takeout? Ha!, Portola Stumbles, and NYT Biotech Ace Moves On

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Danaher Wins Over Abcam, Sage Cuts, & FTC Ceases Fire With Amgen
Rapport’s $150M Advance, Regeneron’s New COVID Challenge, and a Traverse for the Ages
Gilead Bets on Multi-Functionals, Taysha Revived & Google Spotlights Illumina Rival
Sage Gets FDA OK for PPD, Wegovy’s Home Run, & Illumina’s Gloomy Quarter